Cost Management Insights: SG&A Expenses for argenx SE and ACADIA Pharmaceuticals Inc.

Biotech Giants' SG&A Expenses: A Decade of Strategic Growth

__timestampACADIA Pharmaceuticals Inc.argenx SE
Wednesday, January 1, 2014327480004241601.57
Thursday, January 1, 2015908040005392385.38
Friday, January 1, 20161864560007370036.73
Sunday, January 1, 201725506200014970357
Monday, January 1, 201826575800031413266
Tuesday, January 1, 201932563800072279461
Wednesday, January 1, 2020388661000183907682
Friday, January 1, 2021396028000307644000
Saturday, January 1, 2022369090000472132000
Sunday, January 1, 2023402466000709539000
Loading chart...

Infusing magic into the data realm

Navigating the Financial Landscape: SG&A Expenses of Biotech Giants

In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. Over the past decade, ACADIA Pharmaceuticals Inc. and argenx SE have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. Meanwhile, argenx SE exhibited an even more dramatic increase, with expenses skyrocketing by approximately 16,600% during the same period. This stark contrast highlights the aggressive expansion and strategic investments made by argenx SE, particularly in recent years. As these companies continue to navigate the competitive biotech landscape, understanding their cost management strategies offers valuable insights into their operational priorities and future growth potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025